Levi & Korsinsky, LLP
22.7.2021 11:42:54 CEST | ACCESS Newswire | Press release
NEW YORK, NY / ACCESSWIRE / July 22, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
JRVR Shareholders Click Here: https://www.zlk.com/pslra-1/james-river-group-holdings-ltd-information-request-form?prid=17869&wire=1
ATHA Shareholders Click Here: https://www.zlk.com/pslra-1/athira-pharma-inc-loss-submission-form?prid=17869&wire=1
BZ Shareholders Click Here: https://www.zlk.com/pslra-1/kanzhun-limited-information-request-form?prid=17869&wire=1
* ADDITIONAL INFORMATION BELOW *
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.James River Group Holdings, Ltd. (NASDAQ:JRVR)
JRVR Lawsuit on behalf of: investors who purchased August 1, 2019 - May 5, 2021
Lead Plaintiff Deadline: September 7, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/james-river-group-holdings-ltd-information-request-form?prid=17869&wire=1
According to the filed complaint, during the class period, James River Group Holdings, Ltd. made materially false and/or misleading statements and/or failed to disclose that: (1) James River had not adequately reserved for its Uber policies; (2) James River was using an incorrect methodology for setting reserves that materially understated the Company's true exposure to Uber claims; (3) as a result, James River was forced to increase its unfavorable reserves in subsequent quarters even after cancelling the Uber policies; and (4) as a result of the foregoing, Defendants' statements about James River's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.
Athira Pharma, Inc. (NASDAQ:ATHA)
This lawsuit is on behalf of investors who purchased Athira Pharma, Inc. (NASDAQ: ATHA) between September 18, 2020 and June 17, 2021 and/or purchased common stock in or traceable to the Company's registration statement issued in connection with the Company's September 2020 initial public offering priced at $17.00 per share.
Lead Plaintiff Deadline : August 24, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/athira-pharma-inc-loss-submission-form?prid=17869&wire=1
According to the filed complaint, (1) the research conducted by Defendant Kawas, which formed the foundation for Athira's product candidates and intellectual property, was tainted by Kawas' scientific misconduct, including the manipulation of key data through the altering of Western blot images; and (2) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and omitted material facts necessary in order to make the statements made not misleading.
Kanzhun Limited (NASDAQ:BZ)
BZ Lawsuit on behalf of: investors who purchased June 11, 2021 - July 2, 2021
Lead Plaintiff Deadline: September 10, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/kanzhun-limited-information-request-form?prid=17869&wire=1
According to the filed complaint, during the class period, Kanzhun Limited made materially false and/or misleading statements and/or failed to disclose that: (1) Kanzhun would face an imminent cybersecurity review by the Chinese government ("CAC"); (2) the CAC would require Kanzhun to suspend new user registration on its BOSS Zhipin app; (3) Kanzhun needed to "to conduct a comprehensive examination of cybersecurity risks"; (4) Kanzhun needed to "enhance its cybersecurity awareness and technology capabilities"; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/656622/CLASS-ACTION-UPDATE-for-JRVR-ATHA-and-BZ-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Surmodics Opens Medical Device Coating Capabilities in Ireland10.9.2026 16:00:00 CEST | Press release
The Galway Facility Brings Nearly 50 Years of Coating Expertise, Cleanroom Coating Services and Analytical Testing Closer to Medical Device Manufacturers Across Ireland and Europe BALLINASLOE, COUNTY GALWAY, IRELAND / ACCESS Newswire / September 10, 2026 / Surmodics, Inc. today announced its expanded medical device coating capabilities in Galway, Ireland, expanding access to the company's Performance Coatings and coating services for medical device manufacturers throughout Ireland and Europe. The facility now includes dedicated cleanroom environments designed for medical device coating services and brings Surmodics' nearly 50 years of coating experience closer to one of the world's leading medical technology hubs. "Ireland is home to a significant concentration of medical device manufacturers and technology innovators, making it an important market for Surmodics and our customers," said Damien Kilcommons, Vice President of Site Operation at the Ireland facility. "By establishing dedica
MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 202610.9.2026 15:20:00 CEST | Press release
New modular approach will bring together MicroVision lidar hardware, perception software and open sensor integration to enable flexible perception solutions across applications REDMOND, WA AND HANOVER, GER / ACCESS Newswire / September 10, 2026 / MicroVision, Inc. (NASDAQ:MVIS), a leader in advanced perception technologies, today announced plans to unveil its MicroVision Perception Platform™ at IAA Transportation 2026 in Hanover, Germany next week, marking the next evolution of the company's Lidar 2.0 strategy. The new modular platform is designed to bring together MicroVision's expanding portfolio of lidar hardware, perception software and open sensor integration into a flexible architecture that can be configured around the requirements of individual applications spanning automotive, commercial vehicles, industrial, security, defense and aerial use cases. Rather than relying on a fixed sensor configuration or closed "black box" solution, the MicroVision Perception Platform is being d
GA-ASI Unveils Wildfire UAS for Military, Civil and Commercial Roles10.9.2026 15:00:00 CEST | Press release
New Uncrewed Aircraft Combines Exceptional Endurance and Range with Unsurpassed Payload and Affordability at Scale SAN DIEGO, CA / ACCESS Newswire / September 10, 2026 / The world leader in Uncrewed Aircraft Systems, General Atomics Aeronautical Systems, Inc. (GA-ASI) is pleased to announce its groundbreaking Wildfire UAS, a clean-sheet aircraft designed to maximize future investments in large uncrewed aircraft that incorporates lessons learned over decades of large-scale global UAS operations. Wildfire draws upon more than 30 years of delivering more than 1,600 world-changing uncrewed aircraft, including the MQ-1B Predator®, MQ-9A Reaper®, MQ-9B SkyGuardian®, MQ-20 Avenger® and FQ-42A Collaborative Combat Aircraft. GA-ASI aircraft have amassed nearly 10 million total flight hours, mostly in combat, and introduced many of the technologies and concepts now emulated by others around the world. "This is exactly the right design for high-demand missions and cost-conscious customers," said
Steelcase Names Proven Growth Leader Irene Tasi as President9.9.2026 21:00:00 CEST | Press release
Experienced commercial and innovative leader will guide the Steelcase business as the company builds on its design leadership, dealer network and customer-focused strategy. GRAND RAPIDS, MI / ACCESS Newswire / September 9, 2026 / Steelcase today announced Irene Tasi has been named president of Steelcase and will lead the business effective September 14, 2026. Tasi brings more than 25 years of executive leadership experience with a track record leading complex businesses through growth, portfolio development, commercial execution, and organizational change. Her background includes full P&L responsibility, enterprise strategy, innovation, and sales and channel leadership. She will report to Jeff Lorenger, Chairman, President and Chief Executive Officer, HNI Corporation. "Irene brings a combination of commercial leadership, product innovation, operating discipline, and customer focus that makes her exceptionally well-suited to lead Steelcase," said Lorenger. "She has led businesses where
Global Study: Nursing Shortages Require Workforce Policy Solutions, Not Recruitment Campaigns Alone9.9.2026 15:01:00 CEST | Press release
Why people choose nursing, and why they leave, comes down to the same factors PHILADELPHIA, PA / ACCESS Newswire / September 9, 2026 / The global nursing shortage cannot be solved simply by encouraging more people to enter the profession, according to a new evidence brief from the Global Nursing Workforce Centre (GNWC), a joint initiative of the International Council of Nurses (ICN) and TruMerit®. Drawing on research from 42 countries, the brief, The Attractiveness of Nursing for Prospective and Current Nursing Students, finds that the factors influencing people to choose nursing are often the same ones that determine whether they stay. Working conditions, compensation, professional respect, career development opportunities, workplace experiences, and the ability to provide quality care all shape nursing attractiveness to current nurses as well as potential recruits. The findings suggest that countries seeking to strengthen their nursing workforce must focus not only on recruitment, bu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom